LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
29.73
+0.85 (2.94%)
May 2, 2025, 4:00 PM EDT - Market closed

LENZ Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-49.77-69.97-10.81-7.56
Depreciation & Amortization
0.060.020.010
Loss (Gain) From Sale of Assets
0.02---
Loss (Gain) From Sale of Investments
-4.02-1.06--
Stock-Based Compensation
6.371.340.720.2
Other Operating Activities
1.05-0.12-0.020.82
Change in Accounts Payable
-4.280.864.30.38
Change in Other Net Operating Assets
-8.818.551.720.77
Operating Cash Flow
-59.39-60.38-4.09-5.39
Capital Expenditures
-0.47-0.03-0.04-0.01
Investment in Securities
-154.01-29.59--
Investing Cash Flow
-154.48-29.62-0.04-0.01
Issuance of Common Stock
83.550.20.13-
Other Financing Activities
115.45-2.48--
Financing Cash Flow
19980.730.2622.77
Net Cash Flow
-14.87-9.326.1317.36
Free Cash Flow
-59.86-60.41-4.13-5.4
Free Cash Flow Margin
---27.52%-
Free Cash Flow Per Share
-2.81-30.84-0.44-0.58
Levered Free Cash Flow
-40.65-34.210.1-
Unlevered Free Cash Flow
-40.65-34.210.1-
Change in Net Working Capital
9.98-9.73-5.96-
Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q